As previously reported, Benchmark downgraded NeoGenomics (NEO) to Hold from Buy and removed the firm’s prior $18 price target on the shares. The company has gross margins below its peer group average with in-line consensus sales growth for 2025, notes the analyst, who views the stock as fairly valued given these factors. Shares of NeoGenomics, which fell 20% last Friday following the “surprise announcement” that Chris Smith is stepping down from his role as CEO, are down another $2.34, or 16%, to $12.43 in Monday morning trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue